
Lo.Li. Pharma
We are an Italian company, based in Rome, involved in the development and marketing of medical devices and food supplements.
Scientific research, know-how and quality have always been our hallmark and enabled us to pursue our most important goal which is to create safe and effective formulations that meet the needs of medical doctors and patients.
We have been operating for years in the field of obstetrics and gynaecology, where we acquired particular recognition in the field of female and male fertility. In recent years our scientific commitment has expanded to other therapeutic areas, including endocrinology, urology and andrology. In recent years our scientific commitment has expanded to other therapeutic areas, including endocrinology, urology and andrology.
The strength of our company is the passion of its founder for scientific research, supported by a young and dynamic group, committed to guaranteeing the highest levels of quality, safety and effectiveness of the specialities developed and placed on the market. We work in a rigorous and effective way, in compliance with ethical and moral principles.
Therapeutic areas

Female fertility

Gynaecology and Obstetrics

Male Fertility and Andrology

Endocrinology

Urology
DIETARY SUPPLEMENTS
MEDICAL DEVICES
Insights
Vitamina D, azione sull’impianto e sulla recettività endometriale
Vitamina o ormone? La vitamina D è una molecola che è stata a lungo associata alla salute delle ossa e al trattamento di patologie associate al calcio quale, ad esempio, il rachitismo. In realtà, i...
Vitamina D e tiroide: questo nodo ancora da sciogliere
La vitamina D a oggi è una tra le molecole più studiate e discusse in ambito sperimentale e clinico. Seppur ancora si usa chiamarla vitamina, a oggi è ormai chiaro che quando si parla di vitamina D...
Stato dell’ART in Italia: evoluzione della natalità e cause di infertilità
Record negativo per la natalità in Italia: nel 2021 i nati sono 400.249, facendo registrare un calo dell’1,1% rispetto all’anno precedente. Le stime per il 2022 non sembrerebbero mostrare dati più...